Metformin And SitagliptinJanumet
Type 2 diabetes mellitus in patients whose HbA1c is greater than 7% despite treatment with metformin, for initiation of a dipeptidyl peptidase 4 inhibitor, thiazolidinedione, or glucagon-like peptide-1 where metformin and sulfonylurea combination is contraindicated or not tolerated.
Decision on record
- Meeting Mar 2009 Recommended Diabetic drug no PSD
Access path
- TGA registered · Janumet
TGA label narrower than the PBS population
- Nov 2013Recommended
vs alogliptin with metformin fixed dose combination; also…
- PBS listing · Authority Required
Cost-effectiveness
Cost-minimisation analysis conducted; no ICER range reported as this was not a cost-utility analysis
For the reasons outlined below, the PBAC considered that the cost-effectiveness of the metformin XR/sitagliptin FDC would be acceptable if it were cost-minimised against the alogliptin/metformin FDC. PBAC · 2013
Decision context
PopulationAdult patients with Type 2 diabetes mellitus whose HbA1c is greater than 7% despite treatment with metformin, where a combination of metformin and a sulfonylurea is contraindicated or not tolerated, requiring initiation of a gliptin, glitazone, or glucagon-like peptide-1.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2013 | Recommended | alogliptin with metformin fixed dose combination; also metformin immediate release/sitagliptin FDC and individual compon | — | Single-arm · Surrogate |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to HbA1c >7% despite metformin monotherapy, where sulfonylurea combination is contraindicated or not tolerated.